Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metast

Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's a

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market

Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after

Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's aft

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark

Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio

TransCode Therapeutics (NASDAQ: RNAZ) stockholders approved all proposals presented at the company's

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis B

TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients;

TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, sho

TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, sho

BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage c

TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.6

TransCode Therapeutics, Inc.15,955,543 SharesCommon StockThis prospectus relates to the possible res

BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage

TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pio

BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a

TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT

TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI -

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the pote

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the pote

BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage

As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will e

BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clin

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous

BOSTON , Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage

BOSTON , Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap

TransCode Therapeutics Inc. (NASDAQ: RNAZ - Get Free Report) shot up 0.9% on Friday. The stock trade

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA

Safety primary endpoint achievedMedian treatment duration of 4 months with a range of 2 to 12 months

Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 month

TransCode Therapeutics Inc. (NASDAQ: RNAZ) to acquire Polynoma LLC and receive $25 million investmen

BOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (&#34